KALA News and Press, Kala Pharmaceuticals Inc. From 06/10/20

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that its 2020 Annual Meeting of Stockholders (including any adjournments or postponements, the &#x...

Aurinia Files Application for Voclosporin Approval Aurinia Pharmaceuticals Inc. ( AUPH ) announced that it has submitting a New Drug Application for voclosporin for treating kidney inflammation. The company submitted the data obtained from a global clinical program including the pivotal ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Virtual Healthcare Conference. Mark Iwicki, Chairman, Presid...

The FDA accepts for review Kala Pharmaceuticals' (NASDAQ: KALA ) marketing application seeking approval to use Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% to treat the signs and symptoms of dry eye disease. More news on: Kala Pharmaceuticals, Inc., Healthcare stocks news,...

-- FDA Sets PDUFA Goal Date of October 30, 2020 -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administrati...

The sole difference between myself and a madman is the fact that I am not mad! "― Salvador Dali It has been a few months since we circled back on an attractive 'Busted IPO'. The stock has staged a big rally so far in 2020 despite the turmoil in the markets caused by the fallout f...

Kala Pharmaceuticals, Inc. (KALA) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Niranjan Kameswaran - Senior Vice President, Strategy Mary Reumuth - Chief Financial Officer Mark Iwicki - Chairman, President and Chief Executive Officer Kim Brazze...

Image source: The Motley Fool. Kala Pharmaceuticals, Inc.   (NASDAQ: KALA) Q1 2020 Earnings Call May 07, 2020 , 8:00 a.m. ET Operator Continue reading

The following companies have recently filed for mixed shelf offerings: More news on: Albireo Pharma, Inc., ARCA biopharma, Inc., Owens & Minor, Inc., Healthcare stocks news, , Read more ...

-- Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary and Key Secondary Endpoints -- -- EYSUVIS TM NDA Resubmitted on April 30 th ; Potential Approval and Launch Before Year-End -- -- R...